Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @oNKo_innate
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @oNKo_innate
-
Congratulations to our SAB member Professor
@FabienneMackay on her appointment as CEO of@QIMRBerghofer. What a fantastic opportunity to shape medical research in Australia. From all the@oNKo_innate team congrats and best wishes!https://twitter.com/QIMRBerghofer/status/1222760811552051201 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Our CSO
@Dr_Nick_Bikes will explain how the role of NK cells in cancer immunity evolves with tumor progression at the American Association of Immunology annual meeting in Hawaii this May for the Society for Natural Immunity (SNI).https://www.immunology2020.org/scientific-program/ …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hhex Is Essential for NK Cell Persistence by Repressing Bcl2l11-Dependent Apoptosis by Wilford Goh, Jacob T… http://disq.us/t/3l0j9rl
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
All the best for 2020 from the
@oNKo_innate team! Looking forward to updating you all as we advance our NK cell immunotherapies for cancer.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
https://www.biorxiv.org/content/10.1101/406934v1 … Viral-free primary human NK cell genetic modification. Over a year since this pre-print
@Dr_Nick_Bikes revealed a novel, efficient approach to generate next generation NK cell therapiesHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
https://www.jci.org/articles/view/128895 … Can the tumor microenvironment (TME) skew NK cells into suppressors of tumor immunity? TME does alter NK cell phenotype and function. Preventing this could pave the way for improved immunotherapy response rates
#NKcellcheckpoints#cancerimmunotherapyHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Can't argue with that. The biotech sector would welcome some more impactful government support. So few biotech success stories in Oz.......https://twitter.com/Dr_Nick_Bikes/status/1199154765852110850 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
https://innate-killer.com/whats-on/speakers/ … Our CSO
@Dr_Nick_Bikes is presenting at the annual Allo Cell Therapy Industry meeting in San Diego next March#innatekiller early-bird rego closing in 5 days.Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
oNKo sends a hearty congrats to the team at
@FateThx on the FT500 trial. A huge milestone for the cell therapy field.#iPSChttps://health.ucsd.edu/news/releases/Pages/2019-04-01-UC-San-Diego-Health-Treats-Cancer-Patient-with-Stem-Cell-Derived-Natural-Killer-Cells.aspx …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The reason immunotherapy is such as significant advance is that it is effective in late-stage cancers where all other therapies have failed and previously viewed as terminal cancers. Immunotherapy results is a rapid and durable response.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Immunotherapy drug development has increased 91% over the past 2 years from 2030 investigational drugs to 3876 and resulted in a monumental swing in the focus of immunology and cancer researchers.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
The sun rising over our new home
#CrystalPalace@MonashUni The birthplace of innovation and next generation of NK cell immunotherapieshttps://twitter.com/JoeCursons/status/1184939680740937730 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Impact of Tumor and Immunological Heterogeneity on the Anti-Cancer Immune Response https://www.mdpi.com/2072-6694/11/9/1217 … Fascinating review by @CarolynShembrey
@Dr_Nick_Bikes and Frédéric Hollande@VicCompCancerCr@UniMelbMDHS@MonashBDI@MonashUni@MelbImmunoNetHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
#nk2019 was a tour de force! much pre-clinical activity in the CAR NK/allo-NK cell space. very promising phase I data from Katy Razvani on the partial matched CAR19(IL-15) NK cells. Lots of complete responses. 100% safety! CAR NK cells are coming. off-the-shelf & into the clinic!Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
CAR T cells work better when they are NK cells! Everyone wanting IN on the NK game. https://www.jci.org/articles/view/126350 …pic.twitter.com/6K1q4Mg3R4
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
NK cell activity (frequency and function) is required for regression of solid tumors following immune checkpoint blockade (ICB). That's a pretty big deal! Our NK cell therapies should synergize with current market leading ICB approaches to increase response rates.https://twitter.com/oNKo_innate/status/1168851218438868998 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironmenthttps://stm.sciencemag.org/content/11/501/eaav7816 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Congrats
@MonashBDI Another suppressive TME factor to consider. Great workhttps://twitter.com/Dr_Nick_Bikes/status/1166630262576431104 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.